4004 ESC Guidelines label use of medication should be limited to situations where it is in
the patient's interest to do so, with regard to the quality, safety, and efficacy of care, and only …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …

The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …

Transthyretin amyloid cardiomyopathy (ATTR-CM) results in a restrictive cardiomyopathy
caused by extracellular deposition of transthyretin, normally involved in the transportation of …

Despite the many advances in cardiovascular medicine, decisions concerning the
diagnosis, prevention, and treatment of left ventricular (LV) thrombus often remain …

This international multidisciplinary document intends to provide clinicians with evidence-
based practical patient-centered recommendations for evaluating patients and decedents …

Background: Mutations in desmoplakin (DSP), the primary force transducer between cardiac
desmosomes and intermediate filaments, cause an arrhythmogenic form of cardiomyopathy …

This paper is dedicated to the memory of our friends recently passed away, Drs Guy
Fontaine, Andrea Nava, and Nikos Protonotarios, who played a pioneering role in the …